SK19398A3 - Allergen-xcd32 fusion proteins - Google Patents
Allergen-xcd32 fusion proteins Download PDFInfo
- Publication number
- SK19398A3 SK19398A3 SK193-98A SK19398A SK19398A3 SK 19398 A3 SK19398 A3 SK 19398A3 SK 19398 A SK19398 A SK 19398A SK 19398 A3 SK19398 A3 SK 19398A3
- Authority
- SK
- Slovakia
- Prior art keywords
- fusion protein
- cells
- der
- antigen
- human
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 58
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 58
- 108091007433 antigens Proteins 0.000 claims abstract description 60
- 239000000427 antigen Substances 0.000 claims abstract description 59
- 102000036639 antigens Human genes 0.000 claims abstract description 59
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 claims abstract description 46
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims abstract description 46
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 claims abstract description 45
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 38
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 206010020751 Hypersensitivity Diseases 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 230000007815 allergy Effects 0.000 claims description 19
- 108020003175 receptors Proteins 0.000 claims description 15
- 102000005962 receptors Human genes 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 8
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 7
- 235000020932 food allergy Nutrition 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 230000003266 anti-allergic effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 238000010382 chemical cross-linking Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 201000009961 allergic asthma Diseases 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 108010073807 IgG Receptors Proteins 0.000 abstract 2
- 102000009490 IgG Receptors Human genes 0.000 abstract 2
- 239000013566 allergen Substances 0.000 description 56
- 210000003719 b-lymphocyte Anatomy 0.000 description 49
- 230000030741 antigen processing and presentation Effects 0.000 description 26
- 210000001616 monocyte Anatomy 0.000 description 23
- 230000000638 stimulation Effects 0.000 description 22
- 229960004784 allergens Drugs 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 238000005406 washing Methods 0.000 description 14
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 208000026935 allergic disease Diseases 0.000 description 11
- 238000000576 coating method Methods 0.000 description 11
- 210000000612 antigen-presenting cell Anatomy 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- AQYNZOSCOWGGTP-UHFFFAOYSA-N 2-pyridin-2-ylsulfanylpyridine Chemical group C=1C=CC=NC=1SC1=CC=CC=N1 AQYNZOSCOWGGTP-UHFFFAOYSA-N 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 210000003630 histaminocyte Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 108091008875 B cell receptors Proteins 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 241000283707 Capra Species 0.000 description 6
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 6
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 230000005867 T cell response Effects 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 210000004443 dendritic cell Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 210000004241 Th2 cell Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 108700027921 interferon tau Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 235000018185 Betula X alpestris Nutrition 0.000 description 4
- 235000018212 Betula X uliginosa Nutrition 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 4
- 241000238711 Pyroglyphidae Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 229940046533 house dust mites Drugs 0.000 description 4
- 230000016784 immunoglobulin production Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 230000008884 pinocytosis Effects 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000002109 Argyria Diseases 0.000 description 3
- 101710117545 C protein Proteins 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000000447 Th1 cell Anatomy 0.000 description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000004927 clay Substances 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000005185 salting out Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 241001674044 Blattodea Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 125000002228 disulfide group Chemical group 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 229940046528 grass pollen Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 101150082998 pi gene Proteins 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- WHMDPDGBKYUEMW-UHFFFAOYSA-N pyridine-2-thiol Chemical compound SC1=CC=CC=N1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 2
- 238000011158 quantitative evaluation Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QMXCRMQIVATQMR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-pyridin-2-ylsulfanylpropanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSC1=CC=CC=N1 QMXCRMQIVATQMR-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- RGTVXXNMOGHRAY-WDSKDSINSA-N Cys-Arg Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RGTVXXNMOGHRAY-WDSKDSINSA-N 0.000 description 1
- 241000238740 Dermatophagoides pteronyssinus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001672999 Escura Species 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- MQUYPYFPHIPVHJ-MNSWYVGCSA-N Tyr-Trp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)O MQUYPYFPHIPVHJ-MNSWYVGCSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000013575 birch pollen allergen Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000013568 food allergen Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Insects & Arthropods (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9516760.7A GB9516760D0 (en) | 1995-08-16 | 1995-08-16 | Organic compounds |
| PCT/EP1996/003616 WO1997007218A1 (en) | 1995-08-16 | 1996-08-16 | Allergen-xcd32 fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK19398A3 true SK19398A3 (en) | 1998-09-09 |
Family
ID=10779307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK193-98A SK19398A3 (en) | 1995-08-16 | 1996-08-16 | Allergen-xcd32 fusion proteins |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0846178A1 (no) |
| JP (1) | JPH11513025A (no) |
| KR (1) | KR19990036440A (no) |
| CN (1) | CN1193353A (no) |
| AU (1) | AU6873596A (no) |
| BR (1) | BR9610239A (no) |
| CA (1) | CA2227795A1 (no) |
| CZ (1) | CZ43798A3 (no) |
| GB (1) | GB9516760D0 (no) |
| HU (1) | HUP9802349A3 (no) |
| IL (1) | IL122898A0 (no) |
| NO (1) | NO980566D0 (no) |
| PL (1) | PL324897A1 (no) |
| SK (1) | SK19398A3 (no) |
| TR (1) | TR199800214T1 (no) |
| WO (1) | WO1997007218A1 (no) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9724531D0 (en) | 1997-11-19 | 1998-01-21 | Smithkline Biolog | Novel compounds |
| AU750358B2 (en) | 1997-12-02 | 2002-07-18 | Medarex, Inc. | Cells expressing anti-Fc receptor binding components |
| EP1221317A1 (en) * | 2000-12-28 | 2002-07-10 | SHAN-Beteiligungsgesellschaft m.b.H. | Vaccines containing hybrid polypeptides consisting of at least two different allergenic proteins |
| US8029803B2 (en) | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
| US8025873B2 (en) | 2002-06-20 | 2011-09-27 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
| US8007805B2 (en) | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
| BG65715B1 (bg) * | 2003-09-04 | 2009-08-31 | Чавдар ВАСИЛЕВ | Средство за селективно подтискане на патологични днк - специфични в клетки |
| BG65954B1 (bg) * | 2005-01-05 | 2010-07-30 | Чавдар ВАСИЛЕВ | Средство за селективно подтискане активността на патологични автореактивни в-клетки |
| US9636415B2 (en) | 2006-03-03 | 2017-05-02 | S-Target Therapeutics Gmbh | Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies |
| EP1829895A1 (en) * | 2006-03-03 | 2007-09-05 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies |
| LT2861240T (lt) | 2012-06-15 | 2021-01-25 | Immunomic Therapeutics, Inc. | Nukleorūgštys skirtos alergijoms gydyti |
| RU2650709C2 (ru) | 2012-07-13 | 2018-04-17 | С-Таргет Терапевтикс Гмбх | Иммунорегуляторная вакцина |
| DK2914285T3 (en) * | 2012-11-01 | 2017-02-27 | Veterinærinstituttet | New fusion proteins for the treatment of allergic diseases |
| US9005630B2 (en) | 2012-11-01 | 2015-04-14 | Veterinaerinstituttet | Fusion proteins for the treatment of allergic diseases |
| CN105407919B (zh) | 2013-05-21 | 2019-08-06 | Tyg肿瘤学有限公司 | 胃泌素肽免疫原性组合物 |
| CN113186167B (zh) * | 2021-04-28 | 2021-11-30 | 中国食品药品检定研究院 | 用于测定抗cd20单克隆抗体药物adcp生物学活性的方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994024281A1 (en) * | 1993-04-14 | 1994-10-27 | Immulogic Pharmaceutical Corporation | T cell epitopes of the major allergens from dermatophagoides (house dust mite) |
| EP0759782A1 (en) * | 1994-05-26 | 1997-03-05 | Innogenetics N.V. | New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness |
-
1995
- 1995-08-16 GB GBGB9516760.7A patent/GB9516760D0/en active Pending
-
1996
- 1996-08-16 EP EP96929263A patent/EP0846178A1/en not_active Withdrawn
- 1996-08-16 CN CN96196311A patent/CN1193353A/zh active Pending
- 1996-08-16 PL PL96324897A patent/PL324897A1/xx unknown
- 1996-08-16 KR KR1019980701110A patent/KR19990036440A/ko not_active Application Discontinuation
- 1996-08-16 SK SK193-98A patent/SK19398A3/sk unknown
- 1996-08-16 TR TR1998/00214T patent/TR199800214T1/xx unknown
- 1996-08-16 WO PCT/EP1996/003616 patent/WO1997007218A1/en not_active Application Discontinuation
- 1996-08-16 JP JP9508953A patent/JPH11513025A/ja active Pending
- 1996-08-16 CA CA002227795A patent/CA2227795A1/en not_active Abandoned
- 1996-08-16 AU AU68735/96A patent/AU6873596A/en not_active Abandoned
- 1996-08-16 HU HU9802349A patent/HUP9802349A3/hu unknown
- 1996-08-16 CZ CZ98437A patent/CZ43798A3/cs unknown
- 1996-08-16 IL IL12289896A patent/IL122898A0/xx unknown
- 1996-08-16 BR BR9610239A patent/BR9610239A/pt not_active Application Discontinuation
-
1998
- 1998-02-10 NO NO980566A patent/NO980566D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL324897A1 (en) | 1998-06-22 |
| CZ43798A3 (cs) | 1998-06-17 |
| IL122898A0 (en) | 1998-08-16 |
| GB9516760D0 (en) | 1995-10-18 |
| CN1193353A (zh) | 1998-09-16 |
| JPH11513025A (ja) | 1999-11-09 |
| AU6873596A (en) | 1997-03-12 |
| TR199800214T1 (xx) | 1998-06-22 |
| KR19990036440A (ko) | 1999-05-25 |
| HUP9802349A3 (en) | 1999-04-28 |
| MX9801253A (es) | 1998-05-31 |
| NO980566L (no) | 1998-02-10 |
| WO1997007218A1 (en) | 1997-02-27 |
| BR9610239A (pt) | 1999-06-15 |
| HUP9802349A2 (hu) | 1999-01-28 |
| NO980566D0 (no) | 1998-02-10 |
| CA2227795A1 (en) | 1997-02-27 |
| EP0846178A1 (en) | 1998-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100320631B1 (ko) | 항-Fc수용체항체로구성된치료화합물 | |
| Raghavan et al. | Investigation of the interaction between the class I MHC-related Fc receptor and its immunoglobulin G ligand | |
| KR102198189B1 (ko) | Ｌｉｖ-１에 대한 인간화 항체 및 이의 암을 치료하기 위한 용도 | |
| Redpath et al. | The influence of the hinge region length in binding of human IgG to human Fcγ receptors | |
| JP3421970B2 (ja) | ペプチド免疫原 | |
| Lewis et al. | The different effector function capabilities of the seven equine IgG subclasses have implications for vaccine strategies | |
| JP3457962B2 (ja) | 特定Ｆｃεレセプターのための免疫グロブリン変異体 | |
| SK19398A3 (en) | Allergen-xcd32 fusion proteins | |
| Sgroi et al. | Regulation of CD45 engagement by the B-cell receptor CD22. | |
| Vernersson et al. | Generation of therapeutic antibody responses against IgE through vaccination | |
| US20010014328A1 (en) | Therapeutic multispecific compounds comprised of anti-Fcalpha receptor antibodies | |
| CA2074089C (en) | Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor | |
| WO1989006138A1 (en) | UNIQUE ANTIGENIC EPITOPES ON IgE-BEARING B LYMPHOCYTES | |
| HU230769B1 (hu) | Módosított effektor-funkciójú polipeptid-változatok | |
| JP2003520828A (ja) | Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用 | |
| US5942229A (en) | Method for prolonged suppression of humoral immune response to a thymus-dependent antigen therapeutic agent | |
| Zhang et al. | A recombinant human IgG1 Fc multimer designed to mimic the active fraction of IVIG in autoimmunity | |
| US5260416A (en) | Antigenic epitopes present on membrane-bound but not secreted IgE | |
| Yu et al. | Immunochemical properties of anti-Galα1–3Gal antibodies after sensitization with xenogeneic tissues | |
| AU734853B2 (en) | Methods of prolonged suppression of humoral immunity | |
| SAYERS et al. | The structural basis of human IgE–Fc receptor interactions | |
| Pène et al. | Induction of a cross-reactive idiotype dextran-positive antibody response in two IgH-Cb mouse strains treated with anti-J558 cross-reactive idiotype antibodies. | |
| JPH10509948A (ja) | Ｔ細胞受容体ペプチドに対するヒト抗体およびそれらの調製方法 | |
| WO2000023477A2 (en) | Immunoglobulin variants | |
| CZ20013082A3 (cs) | Peptid |